The treatment of the first seizure: The risks

被引:8
作者
Perucca, Emilio [1 ]
机构
[1] Univ Pavia, Inst Neurol, IRCCS C Mondino Fdn, I-27100 Pavia, Italy
关键词
antiepileptic drugs; first seizure; treatment; adverse effects; risks;
D O I
10.1111/j.1528-1167.2008.01447.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The risks associated with prescribing antiepileptic drugs (AEDs) in a person who had a single unprovoked seizure fall into three domains: (1) the risk that treatment will not be effective in preventing seizure relapse, and the consequences thereof; (2) the risks of a person's life being affected by the psychological, social, and legal aspects of receiving treatment for a seizure disorder; (3) the health risks associated with intake of antiepileptic medication. This article with focus on the latter, addressing in particular concerns related to adverse drug effects. Serious or life-threatening adverse reactions are very uncommon in people started on AEDs, although some (e.g., teratogenic effects) can be a major concern in specific patient groups. Nonserious adverse reactions leading to withdrawal of treatment are relatively common, although in most cases these are reversible following removal of the offending agent. Adverse effects associated with prolonged treatment and not leading to drug withdrawal are an important concern, because such effects are often under-recognized and may affect significantly quality of life. Additional risks relate to the occurrence of drug-drug interactions. In all cases, risks can be minimized by careful selection of the AED to be used (with particular consideration of individual characteristics which contraindicate a specific AED, or predispose to specific adverse effects), gradual dose titration, choice of an appropriate target dose and, most important of all, careful monitoring of clinical response.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 37 条
  • [1] Adab Naghme, 2006, Expert Rev Neurother, V6, P833, DOI 10.1586/14737175.6.6.833
  • [2] Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation:: a risk to consider
    Aguiar, D
    Pazo, R
    Durán, I
    Terrasa, J
    Arrivi, A
    Manzano, H
    Martín, J
    Rifá, J
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (03) : 345 - 350
  • [3] Life-threatening adverse events of antiepileptic drugs
    Arroyo, S
    de la Morena, A
    [J]. EPILEPSY RESEARCH, 2001, 47 (1-2) : 155 - 174
  • [4] Quality of life of people with epilepsy: A European study
    Baker, GA
    Jacoby, A
    Buck, D
    Stalgis, C
    Monnet, D
    [J]. EPILEPSIA, 1997, 38 (03) : 353 - 362
  • [5] Commission on outcome measurement in epilepsy, 1994-1997: Final report
    Baker, GA
    Camfield, C
    Camfield, P
    Cramer, JA
    Elger, CE
    Johnson, AL
    da Silva, AM
    Meinardi, H
    Munari, C
    Perucca, E
    Thorbecke, R
    [J]. EPILEPSIA, 1998, 39 (02) : 213 - 231
  • [6] BATTINO D, 2000, MEYLERS SIDE EFFECTS, P164
  • [7] Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy
    Brodie, M. J.
    Perucca, E.
    Ryvlin, P.
    Ben-Menachem, E.
    Meencke, H. -J.
    [J]. NEUROLOGY, 2007, 68 (06) : 402 - 408
  • [8] Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
    Fritsch P.O.
    Sidoroff A.
    [J]. American Journal of Clinical Dermatology, 2000, 1 (6) : 349 - 360
  • [9] Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy
    Galimberti, Carlo Andrea
    Mazzucchelli, Iolanda
    Arbasino, Carla
    Canevini, Maria Paola
    Fattore, Cinzia
    Perucca, Emilio
    [J]. EPILEPSIA, 2006, 47 (09) : 1569 - 1572
  • [10] Optimizing health outcomes in active epilepsy
    Gilliam, F
    [J]. NEUROLOGY, 2002, 58 (08) : S9 - +